Global Human Embryonic Stem Cell Market to Witness openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
Parathyroid Hormone Global Market Report 2020-30: COVID-19 Growth and Change
New York, Dec. 18, 2020 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Parathyroid Hormone Global Market Report 2020-30: COVID-19 Growth and Change - https://www.reportlinker.com/p05998721/?utm source=GNW
78 billion in 2019 to $1.70 billion in 2020 at a compound annual growth rate (CAGR) of -4.4%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.90 billion in 2023 at a CAGR of 3.9%.
Share:
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to market open on Monday, December 21, 2020.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index
Red Biotechnology Market Size to Hit US$ 510 Billion by 2027 - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Share:
EAGAN, Minn., Dec. 16, 2020 /PRNewswire/ In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC (Prime) has finalized an arrangement with Takeda Pharmaceuticals America, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (NYSE:TAK) ( Takeda ) for the factor replacement product ADVATE
® [Antihemophilic Factor (Recombinant)], which is used in the treatment and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency).
Hemophilia treatment options have increased in recent years, including innovative therapies. However, these innovations come at a high price. Therefore, it is important to establish integrated medical and pharmacy benefit contracts between payers and product manufacturers on existing treatments. The arrangement between Prime and Takeda provides: